Immusoft’s Immune System Programming (ISP™) technology platform has been designed to address the challenges associated with current cell therapies
SAN DIEGO, June 25, 2021 – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced that Scott Oross has been appointed as General Counsel.
SEATTLE–Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs.
RBV Capital (backed by Alexey Repik’s R-Pharm and RVC) invested RUB 105 million (ca. $1.5M) in PanDx, a UK-based company developing a novel catheter to treat acute pancreatitis and other severe conditions of the gastrointestinal tract (GI).
Intellogic LLC, raised 160M rubles (ca $2M) in its Series B investment round to further develop its artificial intelligence platform for the analysis of medical images, Botkin.AI.